Nona Biosciences

???????????????????? ????????? ???????? ?????? ???????? ???? ?????? ???????????????? ????????????????????: - ?????????? ??????????????????????????: Varying antigen expression across tumor cells can lead to inconsistent results. - ?????????????????????????????? ????????????????????: ADCs must penetrate cells and release payloads effectively within the tumor microenvironment. - ???????????????????? ????????????????????: Tumor cells can block ADCs, impacting efficacy and limiting therapeutic potential. Nona Biosciences develops internalization-independent custom linkers with high stability, precise release, and payload compatibility, designed specifically for complex tumor environments. Reach out to explore how we can enhance your ADC pipeline! https://lnkd.in/eyHStt4y #ADC #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies #FullyHuman

A Breakthrough in Medicine: Fully Human HCAb-Based mRNA-LNP ?? mRNA-encoding biologics are changing the game in modern medicine! At Nona Biosciences, we’re harnessing cutting-edge mRNA technology to bring the future of therapeutics to life. Here's how our fully human HCAb-based mRNA-LNP platform is making waves: https://nonabio.com/mrna ?? What Sets Our Technology Apart? 1?? Exceptional Cytotoxicity: Our HCAb TAA x CD3 mRNA-LNP exhibits remarkable cytotoxic effects on TAA-expressing target cells. 2?? Specific Killing Effect: Precision matters! The TAA x CD3 mRNA-LNP targets TAA-positive cells specifically, reducing off-target risks and increasing safety. 3?? Distinct Killing Pattern:?? This approach delivers a unique killing pattern compared to traditional methods, maximizing therapeutic potential. 4?? Potent Anti-Tumor Efficacy:?? In vivo studies show that our mRNA-LNP therapy significantly reduces tumor volume, with efficacy scaling with dosage. With the Harbour HCAb Mice? platform at the core, our innovative solution is shaping the future of targeted, effective cancer treatments. ???? ?? Stay tuned as we continue to advance next-gen therapies! https://nonabio.com/mrna #mRNA #mRNATherapy #CancerTherapy #HCAb #PrecisionMedicine #Antibodies

?? Unlock the Future of CAR-T Therapy with Nona Biosciences! ?? Are you looking to stay at the cutting edge of cancer treatment advancements? Our latest white paper dives deep into how Nona Biosciences is transforming CAR-T therapy using state-of-the-art, fully human heavy chain antibodies (HCAbs) for superior efficacy and safety. Highlights of our innovations: - ??????????????? ????????????????????: Leverages fully human HCAbs to reduce immunogenicity and maximize therapeutic impact. - ??????????????????? ????????????????: Pioneering direct CAR-function-based HCAb screening for faster, more efficient development. - ????????????? ????????????????????: Achieve single-day antibody discovery, optimizing labor and throughput. - ?????????????????????????? ???? ?????????? ????????????????????????????????: Ensures robust, high-performance CAR-T cell therapy. Ready to explore the science behind these breakthroughs? Download the full white paper to learn more about our integrated technologies and how we're driving the future of CAR-T therapies. ?? https://lnkd.in/eNiMxrrF #HCAb #heavychainonly #CARTcell #CART #CARTTherapy #Biotechnology #AntibodyDiscovery #CancerTreatment #Innovation

??TCRm antibodies are revolutionizing cancer immunotherapy by combining T-cell receptor precision with antibody versatility, enabling the targeting of a wider range of intracellular antigens. ??These antibodies can recognize antigens presented by MHC molecules, achieving subnanomolar affinity for greater therapeutic impact. With mechanisms like ADCC, CDC, and peptide-MHC targeting, TCRm antibodies enhance tumor cell destruction. ??They also provide antibody-like stability and a long half-life, while being easier to manufacture than traditional TCR-based therapies, making them scalable for large-scale application. Nona Biosciences is at the forefront of this innovation, advancing cancer treatment with highly specific and promising TCRm designs. Learn more: https://lnkd.in/eT-_VkKp

Introducing our custom linker Solution for advanced bioconjugate therapies While off-the-shelf linkers offer convenience in ADC development, overcoming therapeutic challenges such as internalization efficiency and targeted release requires custom solutions. Nona Biosciences screens peptides based on natural substrates and tumor-associated enzyme structures to develop linkers that optimize payload release specifically within the tumor microenvironment. Contact us today to help your ADCs reach their full potential: https://lnkd.in/eyHStt4y #ADC #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies

The moment is finally here! Join us at Booth #417 and then head over to the Town & Country Room D at 12:30 PM to discover our groundbreaking Novel Enzyme Cleavable Linker for the Development of Next-Gen ADCs against Solid Tumors. ? Whether you have just a brief moment to drop by or want to engage in deeper conversation, we're here to explore how we can help you advance your next ADC therapeutic. ? Looking forward to seeing you there! ? #ADC #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies

TCRm antibodies represent a breakthrough in cancer immunotherapy, combining T-cell receptor specificity with antibody properties to target a wider range of intracellular antigens. Unlike traditional therapies, TCRm antibodies offer unique advantages: - ?????????????? ?????????????? ??????????????????: Recognize intracellular antigens presented by MHC molecules, expanding beyond surface targets. - ???????????? ????????????????: Achieve subnanomolar affinity, potentially enhancing therapeutic effectiveness. - ???????????????? ???????????????????? ???? ???????????? (??????): Enable tumor cell killing through ADCC, CDC, and specific peptide-MHC recognition. - ????????????????-???????? ????????????????????????: Offer a long half-life and stability for sustained action. - ???????????????? ????????????????????: Easier to manufacture than TCR-based therapies, ideal for large-scale applications. Nona Biosciences' TCRm antibodies are leading the way with innovative design and high specificity, holding strong promise for advancing cancer treatment.?? Learn more: https://lnkd.in/eT-_VkKp #TCRm #TCRmimic #antibodies #HCAb #CancerResearch #Immunotherapy #Biotech

Looking forward to PEGS Europe! If you’re working on Antibody drug development with specific interests of TCR Mimic Antibody / Single Domain Antibody applications in Immunotherapies, ?visit me at poster section ·??????A085?Single Domain CD3 Antibody Enables Next-Generation T Cell Engagers for Enhanced Immunotherapies ·??????B080 Discovery of T-Cell Receptor Mimic Antibody Derived T-Cell Engager I will be talking about how our Harbour mice platform leverage the antibody based immunotherapies developments Excited to share ideas and learn from everyone there. Hope to see you! https://lnkd.in/e6FvjGpE #FullyHumanAntibody #PEGSEurope #ImmunoTherapy #Nanobody #TCRMimicAntibody

?? Join Nona Biosciences at World ADC 2024! ?? ?? Booth #417 ??? Presentation: Wednesday, November 6th ? Time: 12:30 PM ?? Speaker: Musheng Bao, Vice President, Head of Biology Topic: Discovery and Preclinical Validation of a Novel Enzyme Cleavable Linker for Development of Next-Gen ADC Against Solid Tumors Summary: Tackling the challenges of poor drug penetration and high tumor heterogeneity in ADC and other biologics, Nona Bioscience has developed a groundbreaking linker technology. This innovative linker leverages a unique cleavage mechanism, utilizing an enzyme abundant in the tumor microenvironment (TME) of solid tumors. Paired with our proprietary payloads, it enables efficient, tumor-specific release, independent of internalization. Our preclinical data shows promising efficacy and safety improvements with this linker-payload system. Don’t miss this opportunity to learn about the next generation of targeted cancer therapies!

An overview of the ???????? ????????? by Nona Biosciences?? HCAb PLUS? is the world’s first fully human heavy chain-only antibody (HCAb) platform, clinically validated and experimentally proven, and enables breakthrough in therapeutic modalities. ?????? ????????????????: ?? HBICE? Technology — Unleashing bispecifics, multispecifics, immunocytokines, and other cutting-edge formats with enhanced structure, size reduction, and chain simplicity. ?? Breakthrough Therapeutic Modalities — Designed for powerful applications in ADCs, RDCs, PROTACs, and other areas demanding precision, efficiency, and adaptability. ?? Superior Performance in CAR Therapies — HCAbs from our HCAb Harbour Mice? deliver reduced immunogenicity, high solubility, tissue penetration, and conjugation benefits, ideal for advanced CAR-based cell therapies. ?? Pioneering mRNA Therapies & Targeted Delivery — The compact size and structural benefits of HCAbs enable next-level mRNA designs and LNP modifications, opening up new avenues in targeted treatments. Nona Biosciences is leading the way with highly stable, low-immunogenic, fully human HCAbs for breakthrough therapies. Explore the future of therapeutic innovation with HCAb PLUS?: https://lnkd.in/ecfYaq5u #antibodies #fullyhuman #fullyhumanantibodies #HCAb #heavychainonlyantibodies #heavychainantibodies #nextgentherapeutics #Therapeutics #NonaBiosciences #HCAbPLUS #BiotechInnovation #ImmuneTherapy #ADC #mRNAtherapey #CARTtherapy #CART